Immunoprecise Antibodies
About: ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
Employees: 101
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
6% more funds holding
Funds holding: 18 [Q3] → 19 (+1) [Q4]
0.65% less ownership
Funds ownership: 6.8% [Q3] → 6.14% (-0.65%) [Q4]
35% less capital invested
Capital invested by funds: $1.21M [Q3] → $786K (-$426K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Benchmark Robert Wasserman 34% 1-year accuracy 15 / 44 met price target | 734%upside $3 | Speculative Buy Reiterated | 1 Apr 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 16% 1-year accuracy 32 / 198 met price target | 1,289%upside $5 | Buy Maintained | 31 Mar 2025 |
Financial journalist opinion
Based on 6 articles about IPA published over the past 30 days









